Q-omics provides the consensus-scored AKIRIN2 profile across patient tissues and cancer cell-line models. AKIRIN2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AKIRIN2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, AKIRIN2 RNA expression shows 20,046 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where AKIRIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKIRIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKIRIN2 survival associations across molecular data types. AKIRIN2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKIRIN2 RNA expression–survival associations across cancer types. High AKIRIN2 expression shows unfavorable associations in ACC, DLBC, LAML, HNSC and MESO, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AKIRIN2 RNA expression.
This table summarizes AKIRIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AKIRIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKIRIN2 shows lower tumor expression in LUAD and higher tumor expression in COAD, HNSC, STAD, KIRP and THCA. The COAD box plot shows higher AKIRIN2 RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with AKIRIN2 in patient tissues and cancer cell lines. In patient samples, AKIRIN2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKIRIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
